RxDoctor Payments Data

Munawar Haider, MD

Family Medicine · Bedford, TXNPI 1124018155

Payments from drug & device makers

$14,064in general payments, 2019–2025

Across 868 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$846
  • Teva Pharmaceuticals USA, Inc.$844
  • AstraZeneca$772
  • Pfizer$729
  • GSK$676
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$480%
  • Food & beverage$13,77398%
  • Education$2432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk79$1,064
Lilly USA, LLC71$846
Teva Pharmaceuticals USA, Inc.35$844
AstraZeneca47$772
Pfizer54$729
GSK35$676
Boehringer Ingelheim36$675
Bayer49$660
Amgen44$621
AbbVie(2 entities)50$617
Sunovion Pharmaceuticals Inc.53$602
Novartis31$544
Abbott23$506
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)19$378
Otsuka America Pharmaceutical, Inc.20$357
Astellas Pharma US Inc17$337
Merck19$321
Sumitomo Pharma America, Inc.15$284
Lundbeck LLC16$278
Antares Pharma, Inc.12$205
Corcept Therapeutics9$202
Dexcom, Inc.9$160
Amarin Pharma, Inc.8$156
Eisai Inc.8$155
UCB, Inc.5$144
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$139
Johnson & Johnson10$131
Exact Sciences6$124
SK Life Science, Inc.4$107
Biohaven Pharmaceutical Holding Company Ltd.4$98
Biogen4$86
Idorsia Pharmaceuticals US Inc4$85
Avanir Pharmaceuticals, Inc.5$85
Avvisto Therapeutics, LLC5$79
Shield Therapeutics Inc1$76
Nestle Healthcare Nutrition Inc.4$72
Mylan Specialty L.p.4$71
Genentech USA, Inc.4$67
Arbor Pharmaceuticals, Inc.4$62
Sanofi-aventis U.S. LLC4$58
Acadia Pharmaceuticals Inc3$56
Halozyme Inc3$53
Acorda Therapeutics, Inc2$48
Harmony Biosciences LLC2$46
Evoke Pharma, Inc.3$44
Globus Medical2$39
Xeris Pharmaceuticals, Inc.2$33
Seqirus USA Inc2$32
CMP Pharma, Inc.2$31
Kowa Pharmaceuticals America, Inc.2$29
Axsome Therapeutics, Inc.1$24
Fidia Pharma USA Inc.1$22
Ultragenyx Pharmaceutical Inc.1$21
Neurocrine Biosciences, Inc.1$21
Baxter Healthcare1$18
Mannkind Corporation1$18
Smith+Nephew1$17
Linus Health, Inc.1$14
Cardiovascular Systems Inc.1$13
Ironwood Pharmaceuticals, Inc1$12

How this compares

$14,064 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$1,504,230
Medicare patients
1,595
Services billed
20,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,394$501,293
JardianceEmpagliflozin349$214,714
OzempicSemaglutide129$150,816
JanuviaSitagliptin Phosphate368$136,057
TrulicityDulaglutide157$126,721
AustedoDeutetrabenazine19$110,261
MyrbetriqMirabegron224$95,386
Trelegy ElliptaFluticasone/Umeclidin/Vilanter133$94,798
XareltoRivaroxaban252$88,641
FarxigaDapagliflozin Propanediol150$86,427
GemtesaVibegron275$71,826
XifaxanRifaximin52$67,741
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog173$50,825
JanumetSitagliptin Phos/Metformin Hcl35$46,943
IngrezzaValbenazine Tosylate12$45,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$729$520,1641,406 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta$675$319,969539 claims
Novo NordiskOzempic, Rybelsus$1,064$193,143154 claims
MerckJanuvia, Janumet$321$183,000403 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$676$160,336262 claims
Lilly USA, LLCTrulicity, Mounjaro$846$146,574176 claims
Teva Pharmaceuticals USA, Inc.Austedo$844$110,26119 claims
AstraZenecaFarxiga, Breztri Aerosphere$772$104,141177 claims
Astellas Pharma US IncMyrbetriq$337$95,386224 claims
Johnson & JohnsonXarelto$131$88,641252 claims
Sumitomo Pharma America, Inc.Gemtesa$284$71,826275 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$139$67,74152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →